TRUMF - Terumo Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
47.29
0.00 (0.00%)
At close: 9:30AM EST
Stock chart is not supported by your current browser
Previous Close47.29
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume40
Market Cap17.645B
Beta0.08
PE Ratio (TTM)30.01
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.39 (0.83%)
Ex-Dividend Date2017-03-29
1y Target EstN/A
Trade prices are not sourced from all markets
  • Terumo Corp. :TRUMF-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017
    Capital Cube28 days ago

    Terumo Corp. :TRUMF-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Terumo Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Terumo Corp. – SQI Diagnostics Inc. (SQD-CA) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1,309.44 million, Net Earnings of USD 150.29 million. Gross ... Read more (Read more...)

  • Zacks Small Cap Research11 months ago

    CTSO: Several Catalysts Will Extend Record Revenue Streak Into 2017

    CytoSorbents (CTSO) reported financial results for the fourth quarter ending December 31st and provided a business update.  Total revenue and product sales continue to show considerable strength, rising for the seventh straight quarter and catalyzed by CytoSorb cartridge (“razor blade”) reorders as well as new customer wins and expansion of the distribution footprint. Both product sales and total revenue set new records in Q4.  Q4 product sales were up 74% yoy and 22% sequentially to $2.6M.  Meanwhile, total revenue (which along with product sales includes grant revenue) grew 75% yoy and 28% sequentially to $3.1M.  As we have stressed in the past, we are encouraged by the high quality product revenue growth – that is, mostly reorders, no channel stuffing or lumpy distributor stocking – which we believe offers a certain level of validation of burgeoning demand and by extension, clinical utility of CytoSorb.

  • We're sorry this is all we were able to find about this topic.